Conatus Pharmaceuticals Receives $20,000,000 Series B Funding Round

  • Feed Type
  • Date
    2/13/2011
  • Company Name
    Conatus Pharmaceuticals
  • Mailing Address
    4365 Executive Drive San Diego, CA 92121
  • Company Description
    The Conatus team pioneered the science of apoptosis and the clinical development of pan caspase inhibitors, validating this first-in-class technology. Conatus has well established relationships with key opinion leaders in the fields of hepatology, infectious disease and inflammation.
  • Website
    http://www.conatuspharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $20,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Conatus will use the proceeds to advance the clinical development of CTS-1027, a novel clinical-stage drug candidate the Company has licensed from F. Hoffman-La Roche, Ltd. and is the subject of multiple Phase 2 clinical trials in hepatitis C (HCV)-infected patients.
  • M&A Terms
  • Venture Investor
    AgeChem Venture Fund
  • Venture Investor
    Aberdare Ventures
  • Venture Investor
    Advent Venture Partners
  • Venture Investor
    Bay City Capital
  • Venture Investor
    Glide Healthcare Partners
  • Venture Investor
    Roche Venture Fund

By posting a comment, you agree to our terms and conditions.